NEA Management Company, LLC — 13F Holdings & Portfolio
CIK 1512848 · latest 13F-HR filed 2026-05-15
NEA Management Company, LLC manages $1.76B in 13F-reported U.S. long-equity assets across 26 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ACLX (19.88%), CELC (14.83%), SGP (10.89%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 2, added to 8, and trimmed 14.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.76B
Long-equity book
26
Distinct positions
2026-03-31
Filed 2026-05-15
+1 / −2 / ↑8 / ↓14
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Arcellx, Inc.$151.1M +76.1%
- ORIC Pharmaceuticals, Inc.$18.5M +54.9%
- Korro Bio, Inc.$6.0M +68.2%
- CVRx, Inc.$4.8M +33.2%
- LeonaBio, Inc.$1.3M +35.8%
Top Trims
- Celcuity Inc.-$91.8M -26.0%
- Gossamer Bio, Inc.-$55.8M -99.4%
- Zenas BioPharma, Inc.-$49.3M -38.5%
- Coursera, Inc.-$19.8M -20.9%
- Savara, Inc.-$13.9M -9.5%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 03940C100 | $349.7M | 19.88% | 3,045,262 | SH |
| 2 | Celcuity Inc. | CELC | 15102K100 | $260.9M | 14.83% | 2,285,561 | SH |
| 3 | Spyglass Pharma, Inc. | SGP | 85220G109 | $191.5M | 10.89% | 7,392,301 | SH |
| 4 | Trevi Therapeutics, Inc. | TRVI | 89532M101 | $157.7M | 8.97% | 13,222,228 | SH |
| 5 | Savara, Inc. | SVRA | 805111101 | $133.6M | 7.60% | 24,471,264 | SH |
| 6 | Monte Rosa Therapeutics, Inc. | GLUE | 61225M102 | $126.5M | 7.19% | 7,692,298 | SH |
| 7 | MBX Biosciences, Inc. | MBX | 55287L101 | $107.9M | 6.13% | 3,614,486 | SH |
| 8 | Zenas BioPharma, Inc. | ZBIO | 98937L105 | $78.7M | 4.47% | 4,023,219 | SH |
| 9 | Coursera, Inc. | COUR | 22266M104 | $74.9M | 4.26% | 12,867,769 | SH |
| 10 | Aurinia Pharmaceuticals, Inc. | AUPH | 05156V102 | $58.8M | 3.34% | 3,969,834 | SH |
| 11 | ORIC Pharmaceuticals, Inc. | ORIC | 68622P109 | $52.2M | 2.97% | 4,118,621 | SH |
| 12 | CRISPR Therapeutics AG | CRSP | H17182108 | $50.4M | 2.86% | 1,058,570 | SH |
| 13 | Phathom Pharmaceuticals, Inc. | PHAT | 71722W107 | $21.8M | 1.24% | 1,960,169 | SH |
| 14 | CVRx, Inc. | CVRX | 126638105 | $19.2M | 1.09% | 2,026,083 | SH |
| 15 | Korro Bio, Inc. | KRRO | 500946108 | $14.7M | 0.84% | 1,297,893 | SH |
| 16 | X4 Pharmaceuticals, Inc. | XFOR | 98420X103 | $13.4M | 0.76% | 3,233,743 | SH |
| 17 | Champions Oncology, Inc. | CSBR | 15870P307 | $9.9M | 0.56% | 1,713,720 | SH |
| 18 | Black Diamond Therapeutics, Inc. | BDTX | 09203E105 | $9.5M | 0.54% | 4,448,757 | SH |
| 19 | Inventiva SA | IVA | 46124U107 | $8.0M | 0.46% | 1,462,586 | SH |
| 20 | Nkarta, Inc. | NKTX | 65487U108 | $7.5M | 0.43% | 3,568,781 | SH |
| 21 | LeonaBio, Inc. | LONA | 04746L203 | $4.8M | 0.27% | 464,398 | SH |
| 22 | Senti Biosciences, Inc. | SNTI | 81726A209 | $3.1M | 0.17% | 3,775,615 | SH |
| 23 | Marker Therapeutics, Inc. | MRKR | 57055L206 | $2.1M | 0.12% | 1,625,678 | SH |
| 24 | OnKure Therapeutics, Inc. | OKUR | 68277Q105 | $2.0M | 0.11% | 478,548 | SH |
| 25 | Gossamer Bio, Inc. | GOSS | 38341P102 | $328.5K | 0.02% | 1,000,000 | SH |
| 26 | ImageneBio, Inc. | IMA | 45175G207 | $250.0K | 0.01% | 50,005 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $1.76B | 26 | 0001072613-26-000458 |
| 2025-12-31 | 2026-02-17 | $1.96B | 27 | 0001072613-26-000191 |
| 2025-09-30 | 2025-11-14 | $1.82B | 29 | 0000897069-25-001705 |